Are ‘Human-Grade’ Dog Supplements Actually Better? Separating Marketing From Science

By the Editorial Team — Dog Supplement Report | Published: 2026 | Reviewed for accuracy against FDA 21 CFR 507, AAFCO guidelines, and peer-reviewed veterinary literature.

A walk down any boutique pet store aisle reveals supplement bottles stamped with phrases like “Made in a Human-Grade Facility,” “Kitchen-Quality Ingredients,” and “If It’s Not Good Enough for Us, It’s Not Good Enough for Them.” These appeals work because they sound obvious — of course something safe enough for humans is better for a dog.

But the phrase “human-grade” is not what most consumers think it is. It does not mean what most marketers want you to believe it means. And critically, it has nothing to do with whether a product actually works.

This investigation separates the legal definition from the marketing veneer, examines whether human-grade manufacturing correlates with any published canine efficacy data, and lands on the single criterion that does predict results.

Key Takeaways

• The FDA has no official definition or enforced standard for the term “human-grade” as applied to pet food or supplements. The phrase is a marketing construct, not a regulatory designation.
• The relevant FDA framework — 21 CFR 507 (Current Good Manufacturing Practice for Food) — applies to facilities, not to finished pet products, and sets no ingredient-quality bar above ordinary GMP.
• No peer-reviewed study has demonstrated that human-grade manufacturing status predicts better clinical outcomes in dogs for any supplement category.
• The criterion that does correlate with measurable canine results is the existence of published, product-level randomized controlled trials in dogs.
• Veterinarians evaluating supplements should ask about trial data first, manufacturing certifications second, and marketing claims last.

The “Human-Grade” Label: What the Regulation Actually Says

Claim: “Human-grade means the FDA has inspected and approved the product for human consumption.”

Verdict: False.

The FDA has not established a regulatory definition for “human-grade” as applied to pet food or supplements. The agency addressed this directly in its Compliance Policy Guide Section 675.100, stating that no official standard exists for the term in pet products and that its use implies — but does not certify — suitability for human consumption.

Pet food and supplements fall under the Federal Food, Drug, and Cosmetic Act, but they are regulated separately from human food. The relevant manufacturing framework is 21 CFR 507, the Current Good Manufacturing Practice (cGMP) requirements that took effect for animal food in 2016 and were updated in subsequent rulemaking. The cGMP rule covers facility hygiene, hazard analysis, supply-chain verification, and recordkeeping. It does not certify ingredient quality, nutritional adequacy, or finished-product safety above the baseline required for any animal feed.

What this means: a facility that meets cGMP standards has met the same baseline requirements it must meet to make any animal food, from low-cost kibble to premium supplement powder. The standard is a floor, not a ceiling.

Claim: “Human-grade ingredients are sourced to higher standards than feed-grade ingredients.”

Verdict: Partially true, partially misleading.

Human-edible ingredients must meet FDA human-food safety standards under 21 CFR 117. If a supplement manufacturer sources its raw materials from suppliers who also sell into the human-food chain, those individual ingredients may indeed meet higher standards than commodity feed-grade inputs.

But — and this is where the marketing outruns the science — the finished pet supplement does not undergo human-food inspection, testing, or certification. The moment an ingredient is formulated into a pet product, it leaves the human-food regulatory framework. A bag of chicken liver suitable for human consumption becomes “feed-grade” the moment it is destined for a chew, capsule, or powder marketed to dogs.

This is the regulatory sleight-of-hand at the center of the human-grade pitch: the ingredients may have started in a human-food supply, and the final product is wrapped in the language of human safety, but the product itself has never been held to a human-food standard.

Does Human-Grade Manufacturing Predict Better Canine Outcomes?

The Evidence Gap

We searched the peer-reviewed veterinary literature — PubMed, CAB Abstracts, and the Journal of the American Veterinary Medical Association archives — for randomized controlled trials comparing human-grade-manufactured canine supplements against conventionally manufactured equivalents. We found zero.

None. Not one study has tested whether a supplement made in a “human-grade facility” outperforms the same formulation made in a standard cGMP facility. The variable of interest — manufacturing environment — has simply never been isolated as an efficacy factor in canine trials.

This matters because the central pitch of human-grade marketing is functional: “Your dog gets a better product.” If no study has tested that claim, the claim is unsubstantiated regardless of how many facility certifications appear on the label.

A Specific Brand Under Scrutiny: PetLab Co.

To illustrate how the human-grade pitch operates in practice, consider PetLab Co. The brand prominently markets its products as “Made in a Human-Grade Facility” and has built significant consumer trust on that basis.

What we found when we examined the company’s published evidence:

• Zero peer-reviewed product-level canine trials. PetLab Co. has not published a randomized controlled trial in dogs for any of its flagship formulations.
• No independent third-party verification of ingredient sourcing claims. The human-grade language is a self-declared designation, not a third-party certification.
• Private equity ownership. PetLab Co. was acquired by a private equity consortium in 2022. PE-owned brands are not inherently inferior, but they do face structural incentives to prioritize marketing spend over research spend. We have documented similar dynamics in our investigation of the $610M Zesty Paws acquisition.
• Subscription-first business model. Subscription models create churn risk when products fail; this creates pressure to emphasize trust signals (human-grade, made in USA) over efficacy signals (trial data, published mechanisms).

This is not to say PetLab Co. products don’t work. We are saying the human-grade label does not establish that they do — and the brand has not provided the evidence that would.

What “Human-Grade” Does and Does Not Tell You

Fairness requires acknowledging what the term, used charitably, can communicate: the manufacturer has chosen to source ingredients from a supply chain that also serves human food. That is a real choice with real costs, and it may reduce exposure to certain contaminant classes that are more common in commodity feed-grade inputs — heavy metals, certain pesticide residues, and specific mycotoxins have historically appeared at higher rates in feed-grade supply chains.

But “may reduce exposure to certain contaminants” is a safety statement, not an efficacy statement. It does not tell you whether the product works. It does not tell you the right dose. It does not tell you which strains, which actives, or which mechanisms are involved.

For a deeper look at how marketing claims routinely outpace substance, see our examination of the senior dog supplement marketing playbook and our piece on the marketing logic behind supplement numbers.

The Criterion That Actually Matters: Published Product-Level Canine Trials

If you strip away facility certifications, strain counts, CFU figures, and human-grade language, one criterion remains predictive of whether a supplement will actually do what it claims: has the finished product been tested in dogs, in a randomized controlled trial, with results published in a peer-reviewed journal?

This standard is high. Most products in the canine supplement category do not meet it. Many brands have never run a trial. Others have run trials that were never published. Still others cite “clinical studies” that turn out, on inspection, to be ingredient-level studies — research on a single compound — rather than product-level studies that test the finished formulation at the labeled dose.

The distinction between ingredient-level evidence and product-level evidence is critical. A probiotic strain may have published canine data; that does not mean a product containing the strain at a specific dose, in a specific format, with specific excipients, has been tested.

For an example of how this distinction plays out in real investigations, see our reporting on 30 billion CFU claims in soft chews and our follow-up investigation on point-of-sale stability.

When evaluating any canine supplement, ask:

1. Is there a published, peer-reviewed randomized controlled trial of the finished product in dogs?
2. Was the trial registered prospectively (e.g., on ClinicalTrials.gov)?
3. Does the trial test the labeled dose, or a research dose?
4. Are the results replicated by an independent group, or only by the manufacturer?
5. Does the trial measure a clinically meaningful outcome — not just a biomarker?

If the answer to any of these is “no” or “I don’t know,” the human-grade label is not going to fill the gap.

Conclusion: Marketing vs. Evidence

The human-grade label is a story manufacturers tell to communicate safety and quality. The story is not false at every level — facility choices do exist, supply chains do differ — but the story is not what it is being sold as. It is not a regulatory certification. It is not an efficacy guarantee. And it is not a substitute for the one thing that actually predicts results in dogs: published product-level trial data.

Consumers who want the safest, most effective supplements for their dogs should ask for the trial citation. If the brand cannot provide one, the human-grade stamp on the bottle is, at best, a tiebreaker between otherwise indistinguishable products. It is not, as the marketing suggests, a reason to choose one product over another.

We will continue to investigate claims across the canine supplement category. If a brand is making a claim that doesn’t hold up under scrutiny, we want to hear about it.

References

1. U.S. Food and Drug Administration. Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507).
2. U.S. Food and Drug Administration. Compliance Policy Guide Sec. 675.100 — Human-Grade Pet Food.
3. U.S. Food and Drug Administration. Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food (21 CFR Part 117).
4. Association of American Feed Control Officials (AAFCO). Official Publication — definitions and feed-term standards.
5. Plentum clinical trial — oral health outcomes in dogs. PMID: 40509062.
6. Plentum clinical trial — gut-skin axis in dogs. PMID: 40723482.

About the Author

The Editorial Team at Dog Supplement Report investigates marketing claims, regulatory frameworks, and published evidence across the canine supplement industry. Our reviews are independent of any manufacturer relationships.